InMed Pharmaceuticals Inc
MWG
Company Profile
Business description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer’s disease, INM-089’s pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Contact
885 West Georgia Street
Suite 1445
VancouverBCV6C 3E8
CANT: +1 604 669-7207
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
13
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,795.20 | 23.20 | 0.26% |
| CAC 40 | 7,662.59 | 3.32 | -0.04% |
| DAX 40 | 23,673.29 | 236.32 | -0.99% |
| Dow JONES (US) | 44,494.94 | 400.17 | 0.91% |
| FTSE 100 | 8,785.33 | 24.37 | 0.28% |
| HKSE | 24,264.65 | 192.37 | 0.80% |
| NASDAQ | 20,202.89 | 166.84 | -0.82% |
| Nikkei 225 | 39,593.72 | 392.61 | -0.98% |
| NZX 50 Index | 12,818.59 | 84.06 | 0.66% |
| S&P 500 | 6,198.01 | 6.94 | -0.11% |
| S&P/ASX 200 | 8,562.00 | 20.90 | 0.24% |
| SSE Composite Index | 3,457.78 | 0.03 | 0.00% |